Cargando…

Identification of Plasma Proteins as Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease Using Liquid Chromatography–Tandem Mass Spectrometry

Blood proteins can be used for biomarkers to monitor the progression of cognitive decline, even in the early stages of disease. In this study, we developed a liquid chromatography–tandem mass spectrometry (LC-MS/MS)-based blood test to identify plasma proteins that can be used to detect mild cogniti...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Makoto, Suzuki, Hideaki, Meno, Kohji, Liu, Shan, Korenaga, Tatsumi, Uchida, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488247/
https://www.ncbi.nlm.nih.gov/pubmed/37685872
http://dx.doi.org/10.3390/ijms241713064
_version_ 1785103433831809024
author Inoue, Makoto
Suzuki, Hideaki
Meno, Kohji
Liu, Shan
Korenaga, Tatsumi
Uchida, Kazuhiko
author_facet Inoue, Makoto
Suzuki, Hideaki
Meno, Kohji
Liu, Shan
Korenaga, Tatsumi
Uchida, Kazuhiko
author_sort Inoue, Makoto
collection PubMed
description Blood proteins can be used for biomarkers to monitor the progression of cognitive decline, even in the early stages of disease. In this study, we developed a liquid chromatography–tandem mass spectrometry (LC-MS/MS)-based blood test to identify plasma proteins that can be used to detect mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Using this system, we quantified plasma proteins using isotope-labeled synthetic peptides. A total of 192 patients, including 63 with AD, 71 with MCI, and 58 non-demented controls (NDCs), were analyzed. Multinomial regression and receiver operating characteristic (ROC) analyses were performed to identify specific combinations of plasma protein panels that could differentiate among NDCs, those with MCI, and those with AD. We identified eight plasma protein biomarker candidates that can be used to distinguish between MCI and AD. These biomarkers were associated with coagulation pathways, innate immunity, lipid metabolism, and nutrition. The clinical potential to differentiate cognitive impairment from NDC was assessed using area under the curve values from ROC analysis, which yielded values of 0.83 for males and 0.71 for females. This LC-MS-based plasma protein panel allows the pathophysiology of AD to be followed through detection of cognitive decline and disease progression markers.
format Online
Article
Text
id pubmed-10488247
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104882472023-09-09 Identification of Plasma Proteins as Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease Using Liquid Chromatography–Tandem Mass Spectrometry Inoue, Makoto Suzuki, Hideaki Meno, Kohji Liu, Shan Korenaga, Tatsumi Uchida, Kazuhiko Int J Mol Sci Article Blood proteins can be used for biomarkers to monitor the progression of cognitive decline, even in the early stages of disease. In this study, we developed a liquid chromatography–tandem mass spectrometry (LC-MS/MS)-based blood test to identify plasma proteins that can be used to detect mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Using this system, we quantified plasma proteins using isotope-labeled synthetic peptides. A total of 192 patients, including 63 with AD, 71 with MCI, and 58 non-demented controls (NDCs), were analyzed. Multinomial regression and receiver operating characteristic (ROC) analyses were performed to identify specific combinations of plasma protein panels that could differentiate among NDCs, those with MCI, and those with AD. We identified eight plasma protein biomarker candidates that can be used to distinguish between MCI and AD. These biomarkers were associated with coagulation pathways, innate immunity, lipid metabolism, and nutrition. The clinical potential to differentiate cognitive impairment from NDC was assessed using area under the curve values from ROC analysis, which yielded values of 0.83 for males and 0.71 for females. This LC-MS-based plasma protein panel allows the pathophysiology of AD to be followed through detection of cognitive decline and disease progression markers. MDPI 2023-08-22 /pmc/articles/PMC10488247/ /pubmed/37685872 http://dx.doi.org/10.3390/ijms241713064 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Inoue, Makoto
Suzuki, Hideaki
Meno, Kohji
Liu, Shan
Korenaga, Tatsumi
Uchida, Kazuhiko
Identification of Plasma Proteins as Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease Using Liquid Chromatography–Tandem Mass Spectrometry
title Identification of Plasma Proteins as Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease Using Liquid Chromatography–Tandem Mass Spectrometry
title_full Identification of Plasma Proteins as Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease Using Liquid Chromatography–Tandem Mass Spectrometry
title_fullStr Identification of Plasma Proteins as Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease Using Liquid Chromatography–Tandem Mass Spectrometry
title_full_unstemmed Identification of Plasma Proteins as Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease Using Liquid Chromatography–Tandem Mass Spectrometry
title_short Identification of Plasma Proteins as Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease Using Liquid Chromatography–Tandem Mass Spectrometry
title_sort identification of plasma proteins as biomarkers for mild cognitive impairment and alzheimer’s disease using liquid chromatography–tandem mass spectrometry
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488247/
https://www.ncbi.nlm.nih.gov/pubmed/37685872
http://dx.doi.org/10.3390/ijms241713064
work_keys_str_mv AT inouemakoto identificationofplasmaproteinsasbiomarkersformildcognitiveimpairmentandalzheimersdiseaseusingliquidchromatographytandemmassspectrometry
AT suzukihideaki identificationofplasmaproteinsasbiomarkersformildcognitiveimpairmentandalzheimersdiseaseusingliquidchromatographytandemmassspectrometry
AT menokohji identificationofplasmaproteinsasbiomarkersformildcognitiveimpairmentandalzheimersdiseaseusingliquidchromatographytandemmassspectrometry
AT liushan identificationofplasmaproteinsasbiomarkersformildcognitiveimpairmentandalzheimersdiseaseusingliquidchromatographytandemmassspectrometry
AT korenagatatsumi identificationofplasmaproteinsasbiomarkersformildcognitiveimpairmentandalzheimersdiseaseusingliquidchromatographytandemmassspectrometry
AT uchidakazuhiko identificationofplasmaproteinsasbiomarkersformildcognitiveimpairmentandalzheimersdiseaseusingliquidchromatographytandemmassspectrometry